hypertrophic cardiomyopathy
Conditions
Interventions
Group A (Betadine + Valsartan treatment group) :Betadine + Valsartan
Group B (Betadine conventional treatment group):Betadine
Sponsors
Fuwai Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) 18 years of age or older; 2) Diagnosed with hypertrophic cardiomyopathy (basal septal hypertrophy type) requiring septal myocardial resection, with no significant surgical complications; 3) Sinus rhythm; 4) Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Pregnant and lactating women; children (65 years old); 2) Valsartan or excipient allergy; 3) Previous use of ACEIs or ARBs; lithium; potassium-preserving diuretics, potassium supplements; non-steroidal anti-inflammatory drugs; 4) Diabetic patients using Aliskiren; 5) Patients with hepatic or renal insufficiency; unilateral or bilateral renal artery stenosis; cholestasis or biliary obstruction; 6) Those with severe sodium deficiency or hypovolemia; 7) History of previous cardiac surgery or chemical ablation; 8) Patients with other serious cardiac diseases or comorbidities; 9) Serious intraoperative complications; 10) Other conditions such as inability to complete one year of follow-up that the investigator considers inappropriate for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Late Gadolinium Enhancement; | — |
Secondary
| Measure | Time frame |
|---|---|
| Left ventricular diastolic function;Non-sustained ventricular tachycardia; | — |
Countries
China
Contacts
Public ContactYanhai Meng
Fuwai Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed